Provided by Tiger Trade Technology Pte. Ltd.

INNOCARE

14.540
-0.370-2.48%
Volume:6.90M
Turnover:102.90M
Market Cap:25.69B
PE:32.80
High:15.420
Open:15.000
Low:14.400
Close:14.910
52wk High:20.180
52wk Low:9.650
Shares:1.77B
HK Float Shares:1.49B
Volume Ratio:1.15
T/O Rate:0.46%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.443
ROE:12.77%
ROA:4.45%
PB:2.87
PE(LYR):32.80
PS:7.92

Loading ...

Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals

Stock News
·
Yesterday

InnoCare Pharma (SEHK:9969) Stock Jumps As Profit Arrives And Pipeline Risk Persists

Simply Wall St.
·
Yesterday

Movement Alert|INNOCARE Rises 5.08% in Regular Trading, H1 Earnings Show Return to Profitability with Revenue Up 55.5%

Market Focus
·
Yesterday

Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved

Dow Jones
·
Aug 24

InnoCare Pharma Returns to Profit in H1

MT Newswires Live
·
Aug 24

InnoCare Pharma Swings to RMB 239.67 Million Profit on 55.5% Revenue Jump in H1 2026

Bulletin Express
·
Aug 24

China's InnoCare Pharma H1 Revenue Surges, Partly on Orelabrutinib Growth

Reuters
·
Aug 24

INNOCARE Posts Interim Results with Profit Turnaround on Adjusted Basis

Stock News
·
Aug 24

InnoCare Schedules 24 Aug 2026 Board Meeting to Review 1H 2026 Interim Results

Bulletin Express
·
Aug 11

Why InnoCare Pharma (SEHK:9969) Is Up 12.9% After Dual Breakthrough Therapy Wins in Cancer and Autoimmune Disease - And What's Next

Simply Wall St.
·
Aug 10

Movement Alert|INNOCARE Rises 5.17% in Regular Trading, Multiple Autoimmune Pipeline Clinical Milestones Driving Sustained Uptrend

Market Focus
·
Aug 10

InnoCare Pharma (SEHK:9969) Following Breakthrough Therapy News And The Undervalued Narrative

Simply Wall St.
·
Aug 07

InnoCare Issues 2.04 Million A-Shares Under Incentive Plan, Lifting Total Outstanding to 1.77 Billion

Bulletin Express
·
Aug 05

Breakthrough Psoriasis Data For Oral TYK2 Drug Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)

Simply Wall St.
·
Jul 29

InnoCare Pharma's Phase III Trial of Fadeucravacitinib Meets Primary Endpoint

MT Newswires Live
·
Jul 28

Hong Kong Stock Market Preview: Disease Prevention 15th Five-Year Plan Issued, SK Hynix Breaches IPO Price on Wall Street

Stock News
·
Jul 28

Movement Alert|InnoCare Pharma Falls 5.04% in Regular Trading, Biotech Sector Sell-Off Compounds Post-Catalyst Profit-Taking

Market Focus
·
Jul 17

InnoCare Pharma's Phase II Study of Vitiligo Drug Shows Consistent Safety, Efficacy

MT Newswires Live
·
Jul 16

Innocare's TYK2 Inhibitor Soficitinib Meets Primary Endpoint in Phase II Vitiligo Study

Stock News
·
Jul 16

Phase III Trial for Innocare's Atopic Dermatitis Drug Meets Primary Endpoint

Stock News
·
Jul 15